ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2507

Activated Cullin-Ring Ubiquitin Ligases (CRLs) Dampen T Cell Signaling and Inactivation of Crls Arrests the Progression of Inflammatory Arthritis

Leonard L. Dragone1, Lisa K. Peterson2, Allison Berger3 and Samantha F. Friend2, 1Dept of Pediatrics, National Jewish Health, Denver, CO, 2Pediatrics, National Jewish Health, Denver, CO, 3Department of Millennium Pharmaceuticals, Millennium Pharmaceuticals, Inc, Cambridge, MA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: T cells and signal transduction

  • Tweet
  • Email
  • Print
Session Information

Title: T-cell Biology and Targets in Autoimmune Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: The role of Cullin-Ring ubiquitin ligase (CRL) activity in regulating T cell function is largely unexplored. Thus, we sought to determine if cullin neddylation and CRL activity regulates signaling initiated through the T-cell receptor (TCR) complex to modulate T cell activation and effector functions.

Methods: To determine if TCR complex signaling affects CRL activity, we treated T cells in vitro, with a specific neddylation inhibitor (MLN4924), a drug currently undergoing clinical trials for several maligancies, that prevents CRL activation in combination with CD3 activation and measured IL-2 production. We then assessed CRL activity during TCR complex signaling by examining the neddylation status of the cullin subunit of the CRL. In addition, we knocked down the cullin subunit of the CRLs in T cell lines and examined T cell function. Further we treated arthritis prone mice that have a TCR signaling defect with MLN4924 in vivo to assess the impact of CRL inactivation on T cell activation and effector function.

Results: Treating T cells with MLN4924 lowers the threshold for TCR signaling, as evidenced by enhanced IL-2 production and regulatory T cell (Treg) development upon suboptimal TCR stimulation. Moreover, MLN4924 treatment of the arthritis-prone SKG mouse, arrests arthritis progression and decreases the numbers of IL-17 producing T cell effectors in vivo. We found that strong TCR complex signaling results in cullin deneddylation, which renders the CRL inactive. After knocking down cullins in T cell lines, we found that IL-2 production is increased compared to the parental cell line, but some individual cullin knockdowns do not achieve the same enhancement of IL-2 production as MLN4924 treatment, suggesting that multiple CRLs contribute to regulating TCR complex signaling and IL-2 production.

Conclusion: Thus, we propose that strong TCR complex signaling normally triggers cullin deneddylation to shut off CRL activity and the otherwise tonic ubiquitination and degradation of proteins essential for TCR complex signaling and IL-2 production. Ongoing studies are elucidating the specific CRL targets that contribute to the phenotype seen.

Significance: These findings represent the first step in understanding the interplay between neddylation, CRL-mediated ubiquitination and TCR complex signaling. Expanding our knowledge of how CRLs neddylation regulates TCR complex signaling and T cell function will create opportunities for developing drugs to modulate T cell function to treat immune-mediated diseases.


Disclosure:

L. L. Dragone,
None;

L. K. Peterson,
None;

A. Berger,

Millenium Pharmaceuticals,

3;

S. F. Friend,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/activated-cullin-ring-ubiquitin-ligases-crls-dampen-t-cell-signaling-and-inactivation-of-crls-arrests-the-progression-of-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology